ImmunityBio Advances Treatment Options with J-code for ANKTIVA
ImmunityBio, Inc. (NASDAQ: IBRX), a pioneer in immunotherapy, has announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for its innovative treatment, ANKTIVA (nogapendekin alfa inbakicept-pmln). This new J-code, J9028, is set to become effective shortly, signifying a major advancement for patients battling non-muscle invasive bladder cancer (NMIBC).
Understanding the Significance of J-code J9028
The introduction of the J9028 code allows healthcare providers to bill for ANKTIVA efficiently. J-codes serve as unique identifiers utilized by federal and commercial insurance payers, thus streamlining the billing processes for therapies that require intravesical administration, such as ANKTIVA. This is particularly significant for physicians and medical staff managing treatment plans and claims for patients requiring this life-enhancing therapy.
Expert Insights on ANKTIVA’s Role
Dr. Patrick Soon-Shiong, the founder and Executive Chairman of ImmunityBio, emphasized that the J-code marks an important milestone in their mission to expand the possibilities of immunotherapy. By leveraging natural killer (NK) cells, ANKTIVA provides alternative treatment avenues for patients suffering from bladder cancer, enhancing efficacy beyond traditional T-cell activation therapies.
Highlighting the Clinical Efficacy
In the challenging landscape of NMIBC treatment, standard therapies like Bacillus Calmette-Guérin (BCG) have limitations. Richard Adcock, President and CEO of ImmunityBio, noted that up to 40% of NMIBC patients may experience treatment failure with BCG. Furthermore, of those who initially respond, roughly 50% may see a recurrence of their cancer. The introduction of a permanent J-code like J9028 aims to broaden access to ANKTIVA, which demonstrated a remarkable 71% complete response rate in ongoing clinical studies.
Accessibility and Coverage Advancements
Since its launch, ANKTIVA has become increasingly available to patients, gaining coverage across various commercial and government insurance plans, including Veterans Affairs (VA), Department of Defense (DoD), and Medicare. ImmunityBio has successfully secured reimbursement mechanisms covering over 200 million lives, thereby paving the way for higher accessibility amongst patients in need of effective bladder cancer therapies.
About ANKTIVA and its Mechanism
ANKTIVA operates through the cytokine known as interleukin-15 (IL-15), which plays a vital role in mobilizing the immune system, particularly in enhancing the functionality of NK and CD8+ T cells to combat cancer cells. This innovative therapy transcends conventional limits by activating NK cells, thus restoring effector memory T cell function and aiming to achieve a prolonged complete response.
The Mechanism of Action
As a first-in-class IL-15 agonist, ANKTIVA comprises a fusion of an IL-15 mutant and an IL-15 receptor alpha, achieving a high affinity for binding with IL-15 receptors. This unique configuration helps mimic the natural properties of IL-15, enhancing immune cell activation and proliferation for long-term survival against tumor populations. This comprehensive immune response facilitates immunogenic cell death, significantly improving patient outcomes.
About ImmunityBio's Broader Initiatives
ImmunityBio's dedication lies not just in creating effective bladder cancer treatments but also in developing groundbreaking therapies for various oncology challenges. The company has set its goals on facilitating durable immune responses against multiple cancers, which reflects its innovative approach towards patient care and treatment accessibility.
The FDA has recognized ANKTIVA with a Breakthrough Therapy designation, marking it as a leading treatment option for patients with non-muscle invasive bladder cancer who activate natural killer cells and memory T cells for a sustained therapeutic response.
In pursuit of superior solutions, ImmunityBio is rigorously working on developing vaccines and other immunotherapies that aim to lessen or eliminate the need for high-dose chemotherapy, catalyzing a new era of less toxic, more effective cancer treatment pathways.
Frequently Asked Questions
What is ANKTIVA?
ANKTIVA is an innovative immunotherapy that activates the immune system, specifically targeting bladder cancer cells through natural killer cells and memory T cells.
What does the permanent J-code J9028 entail?
The J-code J9028 allows healthcare providers to easily bill for ANKTIVA, thus simplifying the reimbursement process for intravesical treatments.
Who will benefit from ANKTIVA?
Patients with non-muscle invasive bladder cancer who are unresponsive to standard BCG therapy can potentially benefit significantly from ANKTIVA.
What does the future hold for ImmunityBio?
ImmunityBio aims to enhance patient access to new treatments while advancing research in cancer immunotherapy and other related diseases.
How has the response been to ANKTIVA?
Initial clinical studies demonstrate a promising 71% complete response rate in patients treated with ANKTIVA, indicating its potential effectiveness.
